
-
UK economy grows above forecasts, but tariffs threaten progress
-
Toxic algae killing marine life off Australian coast
-
Oil prices tumble on hopes for Iran nuclear deal
-
Russian delegation, without Putin, arrives in Istanbul for Ukraine talks
-
China first-quarter emissions fell despite rising power demand
-
Eurovision voting: when politics and kitsch converge
-
Eurovision: the 16 acts in second semifinal
-
Israel in Eurovision spotlight at second semifinal
-
Can cash handouts replace aid? Kenya offers some answers
-
Cuban cigarillo factory overwhelmed by burning demand overseas
-
Croatian town pays grandparents for childcare
-
Combs's ex Cassie to face intense defense questioning
-
Kinshasa deploys excavators against illegally built homes
-
All eyes on world's top trio as PGA Championship set to begin
-
Ukraine's Loznitsa warns of danger of despots at Cannes
-
'Unscientific' Japan megaquake rumours spook Hong Kong tourists
-
Timberwolves oust Warriors, Celtics down Knicks to stay alive
-
Dengue, chikungunya may soon be endemic in Europe: research
-
End of nuclear in Taiwan fans energy security fears
-
Reddit founder Ohanian buys stake in Chelsea women's team
-
Sun Yang to swim at China championships after doping ban
-
'I thought she'd survive': Story of slain Gaza photojournalist touches Cannes
-
Pandemic accord, tightened budget on menu at big WHO meet
-
Trump to close deal-making Gulf tour in UAE
-
Ex-All Black Mehrtens backing sleeping giant Beziers
-
Piastri in control, Ferrari floundering as F1 arrives in Europe
-
Premier League top-five hopefuls battle for Champions League riches
-
Under pressure from hard-right, Starmer takes cautious approach to EU 'reset'
-
Stocks drop as fresh trade news awaited, oil down on Iran hopes
-
Ukraine, Russia to hold first direct talks since 2022
-
Tatum-less Boston down Knicks to stay alive in playoffs
-
South Korea police arrest two over Son Heung-min 'blackmail'
-
With Trump's second term, Big Tech embraces US exceptionalism
-
Helium One Global Ltd Announces Jackson-2 Flow Test Results & Gas Analysis Update
-
Genflow Biosciences PLC Announces Key SIRT6 Patent Application
-
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
-
System glitch delays Australian-made rocket launch
-
Conceicao tight-lipped over Milan future after cup final defeat
-
Putin not on Kremlin list for Ukraine talks in Turkey
-
Real Madrid delay Barca celebrations with late Liga win over Mallorca
-
Real Madrid delay Barca celebrations with late win over Mallorca
-
Alcaraz sets up Italian Open semi clash with Musetti, Sabalenka falls
-
Putin not named in Russian delegation for Ukraine talks: Kremlin
-
Bologna end 51-year wait for glory with Italian Cup triumph
-
Bologna beat AC Milan to win the Italian Cup
-
Mexican influencer shot dead during live stream
-
Henry agrees record $30 million extension with Ravens
-
McIlroy not trying to be Bryson's best mate with Masters silence
-
Democrats grill Trump's controversial health secretary
-
Trump admin axes safeguards against 'forever chemicals' in drinking water
CMSC | -0.43% | 21.965 | $ | |
RIO | -0.39% | 62.03 | $ | |
BTI | -0.35% | 40.55 | $ | |
CMSD | -0.58% | 22.26 | $ | |
SCS | -1.61% | 10.54 | $ | |
NGG | -0.15% | 67.43 | $ | |
BCC | -3.27% | 90.74 | $ | |
BP | -0.66% | 30.36 | $ | |
RYCEF | -1.61% | 10.53 | $ | |
BCE | -3.39% | 21.26 | $ | |
RBGPF | 100% | 63.81 | $ | |
JRI | -0.86% | 12.77 | $ | |
GSK | -0.36% | 36.22 | $ | |
AZN | -2.25% | 66.23 | $ | |
RELX | 1.24% | 53.06 | $ | |
VOD | -0.22% | 9.04 | $ |

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025.
The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The conference call will be held in English.
Webcast details
Date: Thursday, 17 April 2025
Time: 2.00 pm CEST (1.00 pm BST, 8.00 am ET)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: www.evotec.com.
Conference call details
To join via phone, please pre-register via this link .
You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link .
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
L.Davis--AMWN